The Role of Inflammation in the Progression of Benign Prostatic Hyperplasia

被引：12
作者：
de Nunzio C. [1 ]
Albisinni S. [1 ]
Gacci M. [2 ]
Tubaro A. [1 ]
机构：
[1] Department of Urology, Ospedale Sant'Andrea, II Faculty of Medicine, University La Sapienza, 00189 Rome
[2] Department of Urology, Ospedale Careggi, University of Forence, 50132 Florence
来源：
Current Bladder Dysfunction Reports | 2013年 / 8卷 / 2期
关键词：
Benign prostatic hyperplasia; Chemokine; Cytokine; Immune; Inflammation; LUTS; Prostate;
D O I：
10.1007/s11884-013-0179-6
中图分类号：
学科分类号：
摘要：
Benign prostatic hyperplasia (BPH) is the most frequent urological occurrence in elderly males, and recently prostatic inflammation has been involved in the pathogenesis and progression of the disease. Inflammatory infiltrates determine cytokine release in the prostatic microenvironment, with consequent tissue damage and subsequent chronic tissue healing that results in the development of BPH. Clinical trials have reported an association between prostatic inflammation and the risk of BPH progression. Moreover, men with metabolic syndrome appear to be at increased risk of BPH, probably for the concomitance of systemic inflammation associated with such syndrome. Understanding the immune pathways associated with BPH will aid in identifying novel therapeutic targets and improve the management of the disorder. The aim of this review is to evaluate the available evidence on the role of prostatic inflammation on BPH and its progression and to discuss the possible clinical implications. © 2013 Springer Science+Business Media New York.
引用
收藏
页码：142 / 149
页数：7
相关论文
共 69 条
[1]  
Kramer G., Marberger M., Could inflammation be a key component in the progression of benign prostatic hyperplasia?, Curr Opin Urol, 16, pp. 25-29, (2006)
[2]  
Roehrborn C.G., Clinical management of lower urinary tract symptoms with combined medical therapy, BJU Int, 102, SUPPL. 2, pp. 13-17, (2008)
[3]  
Montorsi F., Roehrborn C., Garcia-Penit J., Et al., The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study, BJU Int, 107, pp. 1426-1431, (2011)
[4]  
Kaplan S.A., Lee J.Y., Meehan A.G., Et al., Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial, J Urol, 185, pp. 1369-1373, (2011)
[5]  
Platz E.A., Joshu C.E., Mondul A.M., Et al., Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men, J Urol, 188, pp. 496-501, (2012)
[6]  
Briganti A., Capitanio U., Suardi N., Et al., Benign Prostatic Hyperplasia and its Aetiologies, Eur Urol, SUPPL. 8, pp. 865-871, (2009)
[7]  
Moore R.A., Inflammation of the prostate gland, J Urol, 38, pp. 173-182, (1937)
[8]  
Nickel J.C., Roehrborn C.G., O'Leary M.P., Et al., The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial, Eur Urol, 54, pp. 1379-1384, (2008)
[9]  
de Nunzio C., Aronson W., Freedland S.J., Et al., The correlation between metabolic syndrome and prostatic diseases, Eur Urol, 61, pp. 560-570, (2012)
[10]  
Schatteman P.H., Hoekx L., Wyndaele J.J., Et al., Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density, Eur Urol, 37, pp. 404-412, (2000)
1234567